HP
ACLX

HealthInvest Partners’s Arcellx ACLX Stock Holding History

HealthInvest Partners’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,717
Closed -$2.72M – 40
2025
Q4 		$2.72M Buy
41,717
+15,985
+62% +$1.28M 0.87% 34
2025
Q3 		$224K Hold
25,732
– – 0.83% 33
2025
Q2 		$1.69M Sell
25,732
-18,439
-42% -$1.15M 0.73% 33
2025
Q1 		$2.9M Buy
44,171
+2,100
+5% +$142K 1.28% 24
2024
Q4 		$3.3M Buy
42,071
+1,841
+5% +$159K 1.56% 20
2024
Q3 		$3.36M Buy
40,230
+17,734
+79% +$1.18M 1.58% 19
2024
Q2 		$1.24M Buy
22,496
+5,000
+29% +$272K 0.76% 30
2024
Q1 		$1.22M Buy
17,496
+6,096
+53% +$387K 0.74% 31
2023
Q4 		$633K Buy
+11,400
New +$514K 0.5% 38
2022
Q4 		$4.4K Buy
+142
New +$3.26K 0.01% 52

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

HealthInvest Partners's ACLX Position: Q1 2026 in Review

HealthInvest Partners sold out of Arcellx (ACLX) in Q1 2026, closing a stake of 41,717 shares — an estimated $2.72M sold.

HealthInvest Partners first reported a position in ACLX in Q4 2022 and held it in 10 quarters. The position peaked at $3.36M in Q3 2024. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • HealthInvest Partners reported no remaining Arcellx position as of Q1 2026 after selling out during the quarter.
  • HealthInvest Partners sold 41,717 Arcellx shares in Q1 2026, an estimated $2.72M.
  • HealthInvest Partners first reported a position in Arcellx in Q4 2022 and held it in 10 quarters.
  • HealthInvest Partners's Arcellx position peaked at $3.36M in Q3 2024.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on HealthInvest Partners's 13F filing for Q1 2026, filed 11 May 2026.